In the BioHarmony Drug Report Database

"Preview" Icon

Umeclidinium

Incruse Ellipta, Rolufta, Rolufta Ellipta (umeclidinium) is a small molecule pharmaceutical. Umeclidinium was first approved as Incruse Ellipta on 2014-04-30. It is used to treat chronic bronchitis and pulmonary emphysema in the USA. It has been approved in Europe to treat chronic obstructive pulmonary disease. It is known to target muscarinic acetylcholine receptor M5, muscarinic acetylcholine receptor M4, muscarinic acetylcholine receptor M1, muscarinic acetylcholine receptor M3, and muscarinic acetylcholine receptor M2. Anoro ellipta’s patents are valid until 2030-10-11 (FDA).

 

Trade Name

 

Rolufta, Rolufta Ellipta
 

Common Name

 

umeclidinium
 

ChEMBL ID

 

CHEMBL1187833
 

Indication

 

chronic bronchitis, chronic obstructive pulmonary disease, pulmonary emphysema
 

Drug Class

 

Quaternary ammonium derivatives: muscarinic receptor antagonists

Image (chem structure or protein)

Umeclidinium structure rendering